SCHEMBL4952167

SCHEMBL4952167

CCn1c(=O)n(Cc2ccco2)c(=O)c2c1nc(C#Cc1ccc(OC)c(OC)c1)n2C

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 15/20 0.54
ADORA2B P29275 14/20 0.54
ADORA1 P30542 2/20 0.48
ADORA3 P0DMS8 2/20 0.48
HTR1A P08908 1/20 0.48
CYP2C9 P11712 1/20 0.48
MAOB P27338 1/20 0.48
PDE4A P27815 1/20 0.48
PDE4D Q08499 1/20 0.48
ALDH1A1 P00352 3/20 0.42
USP2 O75604 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4951774 0.89 ADORA2A (0.47) ADORA2AADORA2BADORA3
SCHEMBL4637336 0.87 ADORA2A (0.60) ADORA2AADORA2BADORA1ADORA3HTR1A
SCHEMBL12233689 0.84 ADORA2A (0.48) ADORA2AADORA2BADORA1ADORA3HTR1A
SCHEMBL12257980 0.83 ADORA2A (0.56) ADORA2AADORA2BADORA1ADORA3HTR1A
SCHEMBL2535848 0.82 ADORA2A (0.52) ADORA2AADORA2BADORA1ADORA3HTR1A
SCHEMBL14887293 0.79 ADORA2A (0.52) ADORA2AADORA2BADORA1ADORA3HTR1A
SCHEMBL4953221 0.77 ADORA2A (0.52) ADORA2AADORA2BADORA1ADORA3HTR1A
SCHEMBL14887294 0.76 ADORA2A (0.48) ADORA2AADORA2BADORA1ADORA3HTR1A
SCHEMBL4636181 0.76 ADORA2A (0.55) ADORA2AADORA2BADORA1ADORA3HTR1A
SCHEMBL4945006 0.76 ADORA3 (0.40) ADORA2AADORA2BADORA1ADORA3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097415-B1 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS UNIV BONN (DE) 2014-10-29 EP claimed
US-20080221134-A1 8-ALKYNYLXANTHINES AND DERIVATIVES RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) 2008-09-11 US claimed
EP-2097415-B1 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS UNIV BONN (DE) 2014-10-29 EP disclosed
US-8044061-B2 Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. UCB PHARMA GMBH (DE) 2011-10-25 US disclosed
US-20080221134-A1 8-ALKYNYLXANTHINES AND DERIVATIVES RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221134-A1 8-ALKYNYLXANTHINES AND DERIVATIVES SLC6A3, PARK7, SLC18A2 ADORA2A 115/4885ADORA2B 279/4885ADORA1 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.